Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

NMJ. 2021; 10(2): 10-15


Preemptive analgesic efficacy of caudal ropivacaine vs bupivacaine- A randomized study in patients undergoing single level lumbar discectomy

Gundlakunta Swathi,Kolli S Chalam,Narayanam Anantha Sai Kiran,Sunil Valentine Furtado.




Abstract

Abstract
Preemptive analgesic efficacy of caudal ropivacaine vs bupivacaine- A randomized study in patients undergoing single level lumbar discectomy

Objective: The objective of the present study was to compare the preemptive analgesic efficacy of single preincisional caudal epidural injection of 0.2% bupivacaine with 0.2% ropivacaine in patients undergoing single level lumbar discectomy.
Materials and Methods: 100 patients of ASA physical status I undergoing single level lumbar discectomy under general anesthesia.Patients were randomized into two groups of 50 each. After tracheal intubation, patients were placed in prone position. Caudal block was given with 50 microgm of fentanyl and 20ml of either 0.2% ropivacaine (group R) or 0.2% bupivacaine (group B).
Results: The mean intraoperative and postoperative heart rates were significantly lower in bupivacaine group compared to ropivacaine group. Incidence of sinus bradycardia (HR

Key words: bupivacaine, caudal analgesia, lumbar discectomy, epidural analgesia, fentanyl, preemptive analgesia, ropivacaine






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.